Pacira BioSciences falls after co cuts jobs amid manufacturing upgrade

Pacira Biosciences

10/07/2025 13:07

** Shares of drugmaker Pacira BioSciences PCRX.O fall ~5% to $22.02 premarket

** PCRX says in an SEC filing that it will cut 71 jobs, or about 8% of its workforce, at its San Diego Science Center after upgrading to larger manufacturing suites for its EXPAREL pain management product

** EXPAREL is an FDA-approved drug used for postsurgical analgesia, which means it helps reduce or prevent pain after surgery, that allows patients to feel more comfortable as they recover

** The company says it expects to take a pre-tax charge of $2.4–$2.8 million in Q3 2025 for severance and related costs

** As of last close, PCRX stock up ~23% YTD

 (Reporting by Padmanabhan Ananthan)

 ((Padmanabhan.Ananthan@thomsonreuters.com))